BAYER AG

OASIS 3 study supports elinzanetant's efficacy and safety over 52 weeks, with no endometrial hyperplasia or hepatotoxicity observed. Data to be presented at 2024 TMS annual meeting.

Transgene appoints Dr. Emmanuelle Dochy as CMO and Dr. Maurizio Ceppi as CSO to advance cancer immunotherapies and precision medicine.

DelveInsight's 'Non-Small-Cell Lung Cancer Pipeline Insight 2024' covers 135+ companies and 150+ pipeline drugs, highlighting key players like BridgeBio Pharma, Daiichi Sankyo, and Merck. Prominent therapies include Trastuzumab deruxtecan, DS-1062a, and Pembrolizumab. Recent studies by Merck, AstraZeneca, and Gilead focus on Phase 3 trials for V940, Durvalumab, and Zimberelimab, respectively.

EMA approves Eylea 8 mg pre-filled syringe for nAMD and DME, offering efficient and precise treatment. Developed by Bayer and Regeneron, Eylea 8 mg extends treatment intervals up to five months with comparable efficacy and safety to Eylea 2 mg. The syringe aims to benefit ophthalmologists and patients with its simplicity and accuracy.

Finerenone reduced HF events and cardiovascular death in patients with HF and mildly reduced or preserved ejection fraction, according to a trial led by Brigham and Women’s Hospital. The drug showed benefits regardless of ejection fraction and even with other therapies, suggesting it could be a new therapeutic option for HF patients. The trial, funded by Bayer, had limitations including few Black participants. Results were presented at the European Society of Cardiology Congress 2024 and published in the New England Journal of Medicine.

Illumina's TruSight Oncology Comprehensive test, approved by the FDA, profiles 517 genes to match cancer patients with targeted therapies or clinical trials, aiding in personalized treatment.

EMA approves Bayer's OcuClick pre-filled syringe for Eylea 8 mg, facilitating accurate administration in wet AMD and DME treatments, with Germany as an early launch market.